View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
November 26, 2021

Sputnik V shows efficacy against Covid-19-linked death in Hungarian study

The vaccine was 100% efficient against disease linked mortality in people aged 16 to 44 years.

The Russian Direct Investment Fund (RDIF) has reported that the Covid-19 vaccine, Sputnik V, demonstrated a 98% efficacy in averting related deaths in an observational study in Hungary.

The independent nationwide study is based on real-world data from the National Public Health Center (NPHC) comprising 3.7 million people inoculated with various vaccines in Hungary.

It analysed and compared the efficacy of five Covid-19 vaccines, namely Sputnik V and vaccines of Moderna, Pfizer-BioNTech, Sinopharm and AstraZeneca.

Findings showed that Sputnik V had an 85.7% efficacy against Covid-19, with a similar trend observed in vaccinations with Moderna’s Covid-19 vaccine.

As part of the countrywide inoculation drive, Hungarian citizens received two doses of either the Sputnik V, Pfizer-BioNTech, Sinopharm, Moderna or AstraZeneca vaccines between 22 January and 10 June 2021.

Nealy 820,000 people were given the two doses of Sputnik V.

Hungarian data showed that Sputnik V offered maximum protection against mortality linked to Covid-19 with an efficacy rate against the disease in line with the Moderna vaccine.

Furthermore, Sputnik V was found to be completely effective against mortality in people of the age group 16 to 44 years.

Russian Direct Investment Fund CEO Kirill Dmitriev said: “With 98% efficacy in preventing Covid-related mortality and 85.7% efficacy against coronavirus infection, Sputnik V has demonstrated the best results among five vaccines administered in EU member state Hungary as part of an independent study based on data from 3.7 million people.”

Hungary is the first country in the EU to grant authorisation to the Sputnik V vaccine.

According to real-world data of the Ministry of the Health of the Republic of San Marino, Sputnik V showed long-term efficacy of 80% against Covid-19 from six to eight months following the second dose.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena